MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 11, 1996, Pages 671-675

  De Kant, Eric ^a   Heide, Immo ^b   Thiede, Christian ^b   Herrmann, Richard ^c   Rochlitz, Christoph F ^c  

^a Academic Hospital Utrecht   (Netherlands)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Colorectal cancer; MDR1; Metastasis; p53

Indexed keywords

PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTASIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; INTESTINAL MUCOSA; NEOPLASM METASTASIS; P-GLYCOPROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029987398     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01209030     Document Type: Article

References (28)

1. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumourigenesis. Cancer Res 50:7717-7722
2. Banerjee S, Ganapathi R, Ghosh L, Yu Cl (1992) Down-regulation of ras and myc expression associated with mdr-1 overexpression in Adriamycin-resistant tumour cells. Cell Mol Biol 38:561-570
3. Burt RK, Garfield S, Johnson K, Thorgeirsson SS (1988). Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis 9:2329-2332
4. Chin KV, Ueda K, Pastan I, Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462
5. Cohen AM, Shank B, Friedman MA (1989) Colorectal cancer. In: DeVita Jr VT, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 895-964
6. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Lehne G, Chen Y, Clausen OPF (1995) P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 72:307-311
7. Efferth T, Volm M (1992) Immunocytochemical detection of oncoproteins in animal and human tumour lines with acquired or inherent multidrug resistance. Cancer Detect Prev 16:237-243
8. Elrouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459
9. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 84:265-269
10. Goldsmith ME, Gudas JM, Schneider E, Cowan KH (1995) Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 270:1894-1898
11. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124
12. Gottesman MM, Pastan I (1988) The multidrug transporter, a double-edged sword. Trends Biochem Sci 263:12163-12166
13. Kramer R, Weber RK, Morse B, Arceci R, Staniunas R, Steele G Jr, Summerhayes IC (1993) Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 67:959-968
14. Lai S, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine J, Ihde DC, Kayser K, Gazdar AF (1989) MDR1 gene expression in lung cancer. J Natl Cancer Inst 81:1144-1150
15. Preudhomme C, Lepelley P, Vachee A, Soenen V, Quesnel B, Cosson A, Fenaux P (1993) Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia 7:1888-1890
16. Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y (1993) Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193
17. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V (1993) c-myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4:57-65
18. Rochlitz CF, De-Kant E, Neubauer A, Heide I, Böhmer R, Oertel J, Huhn D, Herrmann R (1992a) PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia. Ann Hematol 65:241-246
19. Rochlitz CF, Lobeck H, De Kant E, Mohr B, Reuter J, Peter S, Huhn D, Herrmann R (1992b) Multiple drug resistance gene expression in human renal cell cancer is associated with the histological subtype. Cancer 69:2993-2998
20. Rochlitz CF, Heide I, De Kant E, Böhmer R, Peter FJ, Neuhaus P, Huhn D, Herrmann R (1993) Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. Oncology 50:70-76
21. Rochlitz CF, Heide I, Thiede C, Herrmann R, De Kant E (1995) Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. Ann Onco 6:981-986
22. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS (1994) P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumours [see comments]. J Natl Cancer Inst 86:850-855
23. Strauss BE, Haas M (1995) The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins. Biochem Biophys Res Commun 217:333-340
24. Teeter LD, Eckersberg T, Tsai Y, Kuo MT (1991) Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene Pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ 2:429-437
25. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738
26. Volm M (1993) P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. Anticancer Res 13:375-378
27. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LE, Grogan TM, Saclarides TJ, Roninson IB, Coon JS (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumour aggressiveness and lymph node metastasis. Cancer Res 51:2720-2726
28. Zastawny RE, Salvino R, Chen J, Benchimol S, Ling V (1993) The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8:1529-1535